Navigation path

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lithuania
  Luxembourg
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tunisia
  Turkey
  Ukraine
  United Kingdom
  United States

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport


   Countries

Last Update: 19-02-2013  
Related category(ies):
Health & life sciences  |  Success stories

 

Countries involved in the project described in the article:
Belgium  |  Czech Republic  |  Ireland  |  Netherlands  |  Spain
Add to PDF "basket"

How European research is making kidney transplants safer

For those unfortunate to suffer from kidney failure, an organ transplant may seem like the best long-term treatment. But kidney transplants are loaded with risk, the most salient being the rejection of the donor organ by the host’s body. Now, however an Irish-led research project has developed a new drug that could succeed in preventing organ rejection, offering hope to thousands of patients seeking donor kidneys.

©  Fotolia
The project is the result of the collaboration by nine European research and clinical groups under the banner of MABSOT, or Monoclonal Antibody Solid Organ Transplantation. It aims to develop a drug, OPN-305, to treat delayed graft function (DGF), which is defined as the need for dialysis in the first week after surgery. DGF occurs in 40% to 60% of patients receiving a transplant from higher risk donors but OPN-305, an antibody developed to reduce inflammation, could lessen this complication.

The MABSOT consortium is led by Opsona Therapeutics, an Irish drug development SME spun-out from Trinity College Dublin, which last year won an Outstanding Achievement Award at Ireland’s Champions of EU Research event. The consortium aims to ensure transplants from non-living donors – considered more high risk – are used more frequently. “Because of the lack of available organs, surgeons have to use more kidneys that are less than ideal, and there is a risk they don’t work or work poorly,” says Opsona co-founder Luke O'Neill. “Our drug essentially should allow such kidneys to work better from the outset and improves the chances of long term success.”

O'Neill is also Chair of Biochemistry at Trinity College Dublin, Chair of the Immunity and Infection panel of the European Research Council (ERC), an ERC Advanced Grant awardee and also a recent recipient of a Gold Medal Award from the Royal Irish Academy. He explains that OPN-305 works by stopping the inflammatory process from rejecting the kidney, acting to prevent an acute inflammatory reaction, which might stop the kidney from working.

OPN-305 is an antibody to TLR-2, which is one of the key structures of the innate immune system and part of the first line of defence against microbial organisms. When stimulated, TLR-2 induces and propagates inflammation. It is activated through so called external danger signals like microbial cell wall components, as well as through so called internal danger signals resulting from tissue injury. “TLR-2 is present in the kidney, senses the trauma of the transplant and drives the acute inflammation,” says O’Neill. “However, OPN-305 blocks the TLR-2 from working and causing mischief, and so blocks that acute inflammatory process.”

Mary Reilly, Opsona’s Vice President for Pharmaceutical Development and Operations and Coordinator of the Mabsot project, says OPN-305, which has already been granted patents, can be used for other organs too. “Anywhere that you see ischaemia – the starving of oxygen from organs – then the antibody has the potential to protect. You can extend this potential to heart, liver and lung transplants, as well as treatments for heart attacks, stroke or cancer,” she says.

There have so far been several successful transplants performed using OPN-305 as part of the study. Reilly says approval based on successful clinical trials could be by 2019. She says the promise of speedy and effective transplants would be a huge relief to patients, improving their chances of a decent quality of life free from clinics and dialysis machines.

It would also be a remarkable research success story, Reilly notes. “There is a lot of interest in the novel aspects of this product, and it can be considered first and best in class if the clinical study is successful. We really are at the cutting edge of this: there is nothing out there approved for this indication,” she says.

Project details

  • Project acronym: MABSOT
  • Participants: Ireland (Coordinator), United Kingdom, Belgium, Spain, The Netherlands, Czech Republic
  • Project FP7 261468
  • Total costs: €7 817 913
  • EU contribution: €5 929 064
  • Duration: December 2010-November 2013

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Project web site
Project information on CORDIS





  Top   Research Information Center